TY  - JOUR
TI  - Gene therapy for Parkinson’s disease: a new frontier in neurodegenerative diseases
AU  - Asuku, Abraham Olufemi
AU  - Ogungbangbe, Gbonjubola Oyinlola
AU  - Fajemidagba, Grace Ayobami
PY  - 2025
JO  - Exploration of Neuroprotective Therapy
VL  - 5
SP  - 1004119
DO  - 10.37349/ent.2025.1004119
UR  - https://www.explorationpub.com/Journals/ent/Article/1004119
AB  - Parkinson’s disease (PD) is a devastating neurodegenerative condition characterized primarily by the degeneration of the dopaminergic neurons in the substantia nigra, causing motor dysfunction and many non-motor symptoms. Available pharmacological treatments and therapies provide symptomatic relief but do not halt the progression of PD. Gene therapy has been recognized as a valuable therapeutic frontier, providing the possibility of disease modification by targeting the underlying molecular and cellular mechanisms of PD. The parts of the methodology used for gene therapy entail the delivery of genetic material into particular regions of the brain with the aid of viral vectors to improve the synthesis of dopamine, maintain the integrity of neurons, or control pathological pathways. Recent clinical trials have shown promising efficacy and safety profiles for many gene therapy methods, consisting of those targeting enzymes in the biosynthesis of dopamine [e.g., L-amino acid decarboxylase (AADC)], synuclein alpha pathology, and neurotrophic factors [e.g., growth-derived neurotrophic factor (GDNF)]. However, in spite of these developments, there are limitations in vector delivery and prolonged expression of genes, as well as patient-specific responses. This review highlights the present landscape of gene therapy in PD, discussing the latest successes, ongoing clinical trials, and future perspectives that could shape therapeutic paradigms for PD.
ER  -